NOVEL USAGE OF ONCOLYTIC GENE-MODIFIED MEASLES VIRUS

Abstract: an object of the present invention is to develop gene-modified measles viruses (rmv-slamblind and rmv-v(−)-slamblind) that do not recognize slam as a tool for a medical treatment for tumors. the present invention provides a pharmaceutical composition for inducing cell-mediated immunity against a tumor cell to subject the tumor cell to medical treatment, the pharmaceutical composition containing an oncolytic gene-modified measles virus, and also provides a method of inducing cell-mediated immunity against a tumor cell remaining in a living body that could not be eliminated even by direct introduction of an oncolytic gene-modified measles virus, or against a tumor cell that has metastasized or recurred, the method including directly introducing an oncolytic gene-modified measles virus into a tumor cell as a medical treatment target to cause cell death.

Inventor(s): Chieko Kai, Misako Yoneda, Tomoko Fujiyuki, Kanako Moritoh

CPC Classification: A61K39/0011 (Medicinal preparations containing antigens or antibodies (materials for immunoassay ))

Search for rejections for patent application number 20250195634